Advancing treatment options for chronic idiopathic constipation

References

• Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582–1591.
   PubMed Web of Science ®Google Scholar
• Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):11B–15B.
   PubMedGoogle Scholar
• Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, et al. Chronic constipation in the elderly. Am J Gastroenterol. 2012;107:18–25.
   PubMed Web of Science ®Google Scholar
• Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599–608.
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
   PubMed Web of Science ®Google Scholar
• Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology. 2013;145:749–757.
   PubMed Web of Science ®Google Scholar
• Zhao YF, Ma XQ, Wang R, et al. Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: the systematic investigation of gastrointestinal diseases in China (SILC). Aliment Pharmacol Ther. 2011;34:1020–1029.
   PubMed Web of Science ®Google Scholar
• Wong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol. 2010;105:2228–2234.
   PubMed Web of Science ®Google Scholar
• Hinton JM, Lennard-Jones JE. Constipation: definition and classification. Postgrad Med J. 1968;44:720–723.
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144:218–238.
   PubMed Web of Science ®Google Scholar
• Dinning PG, Jones M, Hunt L, et al. Factor analysis identifies subgroups of constipation. World J Gastroenterol. 2011;17:1468–1474.
   PubMed Web of Science ®Google Scholar
• Zarate N, Knowles CH, Newell M, et al. In patients with slow transit constipation, the pattern of colonic transit delay does not differentiate between those with and without impaired rectal evacuation. Am J Gastroenterol. 2008;103:427–434.
   PubMed Web of Science ®Google Scholar
• Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133:761–768.
   PubMed Web of Science ®Google Scholar
• Suttor VP, Prott GM, Hansen RD, et al. Evidence for pelvic floor dyssynergia in patients with irritable bowel syndrome. Dis Colon Rectum. 2010;53:156–160.
   PubMed Web of Science ®Google Scholar
• Dinning PG, Carrington EV, Scott SM. The use of colonic and anorectal high-resolution manometry and its place in clinical work and in research. Neurogastroenterol Motil. 2015;27:1693–1708.
   Google Scholar
• Singh G, Lingala V, Wang H, et al. Use of health care resources and cost of care for adults with constipation. Clin Gastroenterol Hepatol. 2007;5:1053–1058.
   PubMed Web of Science ®Google Scholar
• Doshi JA, Cai Q, Buono JL, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm. 2014;20:382–390.
   PubMed Web of Science ®Google Scholar
• Sethi S, Mikami S, Leclair J, et al. Inpatient burden of constipation in the United States: an analysis of national trends in the United States from 1997 to 2010. Am J Gastroenterol. 2014;109:250–256.
   PubMed Web of Science ®Google Scholar
• Chevalier P, Lamotte M, Joseph A, et al. In-hospital costs associated with chronic constipation in Belgium: a retrospective database study. Neurogastroenterol Motil. 2014;26:368–376.
   PubMed Web of Science ®Google Scholar
• Walsh C, Murphy J, Quigley EM. Pharmacoeconomic study of chronic constipation in a secondary care centre. Ir J Med Sci. 2015;184:863–870.
   PubMed Web of Science ®Google Scholar
• Dik VK, Siersema PD, Joseph A, et al. Constipation-related direct medical costs in 16 887 patients newly diagnosed with chronic constipation. Eur J Gastroenterol Hepatol. 2014;26:1260–1266.
   PubMed Web of Science ®Google Scholar
• Wald A, Sigurdsson L. Quality of life in children and adults with constipation. Best Pract Res Clin Gastroenterol. 2011;25:19–27.
   PubMed Web of Science ®Google Scholar
• Mason HJ, Serrano-Ikkos E, Kamm MA. Psychological morbidity in women with idiopathic constipation. Am J Gastroenterol. 2000;95:2852–2857.
   PubMed Web of Science ®Google Scholar
• Neri L, Basilisco G, Corazziari E, et al. Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United European Gastroenterol J. 2014;2:138–147.
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ, Stelwagon M, Miller SA, et al. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110:580–587.
   PubMed Web of Science ®Google Scholar
• Sommers T, Corban C, Sengupta N, et al. Emergency department burden of constipation in the United States from 2006 to 2011. Am J Gastroenterol. 2015;110:572–579.
   PubMed Web of Science ®Google Scholar
• Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008;28:917–930.
   PubMed Web of Science ®Google Scholar
• Wald A, Mueller-Lissner S, Kamm MA, et al. Survey of laxative use by adults with self-defined constipation in South America and Asia: a comparison of six countries. Aliment Pharmacol Ther. 2010;31:274–284.
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S5–S21.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug;109(Suppl 1):S2–S26.
   PubMed Web of Science ®Google Scholar
• Ashraf W, Park F, Lof J, et al. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther. 1995;9:639–647.
   PubMed Web of Science ®Google Scholar
• Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9:577–583.
   PubMed Web of Science ®Google Scholar
• Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105:897–903.
   PubMed Web of Science ®Google Scholar
• McRorie JW, Daggy BP, Morel JG, et al. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998;12:491–497.
   PubMed Web of Science ®Google Scholar
• Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci. 1996;41:1636–1642.
   PubMed Web of Science ®Google Scholar
• Corazziari E, Badiali D, Bazzocchi G, et al. Long-term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000;46:522–526.
   PubMed Web of Science ®Google Scholar
• DiPalma JA, DeRidder PH, Orlando RC, et al. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol. 2000;95:446–450.
   PubMed Web of Science ®Google Scholar
• Attar A, Lemann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999;44:226–230.
   PubMed Web of Science ®Google Scholar
• Di Palma JA, Cleveland MV, McGowan J, et al. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol. 2007;102:1964–1971.
   PubMed Web of Science ®Google Scholar
• Crowell MD, Shetzline MA, Moses PL, et al. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs. 2004;5:55–60.
   PubMedGoogle Scholar
• Emmanuel AV, Tack J, Quigley EM, et al. Pharmacological management of constipation. Neurogastroenterol Motil. 2009;21(Suppl 2):41–54.
   PubMed Web of Science ®Google Scholar
• Quigley EMM. Cisapride. What can we learn from the rise and fall of a prokinetic? J Dig Dis. 2011;12:147–156.
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745–767.
   PubMed Web of Science ®Google Scholar
• Quigley EMM. Prucalopride: safety, efficacy and potential applications. Ther Adv Gastroenterol. 2012;5:23–30.
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Quigley EMM. Constipation, IBS and the 5-HT4 receptor: what role for prucalopride? Clin Med Insights Gastroenterol. 2010;3:21–33.
   Google Scholar
• Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther. 2001;299:1007–1012.
   PubMed Web of Science ®Google Scholar
• Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012;73:203–209.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. New Engl J Med. 2008;358:2344–2354.
   PubMed Web of Science ®Google Scholar
• Tack J, Van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357–365.
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315–328.
   PubMed Web of Science ®Google Scholar
• Tack J, Quigley EMM, Camilleri M, et al. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. Ueg J. 2013;1:48–49.
   PubMed Web of Science ®Google Scholar
• Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil. 2010;22:42–49.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil. 2007;19:30–38.
   PubMed Web of Science ®Google Scholar
• Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther. 2010;32:1102–1112.
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014;39:239–253.
   PubMed Web of Science ®Google Scholar
• Bang CS, Kim JH, Baik GH, et al. Mosapride treatment for functional dyspepsia: a meta-analysis. J Gastroenterol Hepatol. 2015;30:28–42.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord. 2005;20:680–686.
   PubMed Web of Science ®Google Scholar
• Choi CH, Kwon JG, Kim SK, et al. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil. 2015;27:705–716.
   PubMed Web of Science ®Google Scholar
• Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol. 2008;154:126–135.
   PubMed Web of Science ®Google Scholar
• Bijvelds MJ, Bot AG, Escher JC, et al. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology. 2009;137:976–985.
   PubMed Web of Science ®Google Scholar
• Jakab RL, Collaco AM, Ameen NA. Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility. Dig Dis Sci. 2012;57:2826–2845.
   PubMed Web of Science ®Google Scholar
• Norimatsu Y, Moran AR, MacDonald KD. Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)). Biochem Biophys Res Commun. 2012;426:374–379.
   PubMed Web of Science ®Google Scholar
• Cuppoletti J, Malinowska DH, Chakrabarti J, et al. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat. 2008;86:56–60.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol. 2006;290:G942–G947.
   PubMed Web of Science ®Google Scholar
• Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol. 2009;296:G295–G301.
   PubMed Web of Science ®Google Scholar
• Cuppoletti J, Blikslager AT, Chakrabarti J, et al. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial barrier properties and cellular homeostasis after exposure to cold stressors. BMC Pharmacol. 2012;12:3.
   PubMedGoogle Scholar
• Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–1361.
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–177.
   PubMed Web of Science ®Google Scholar
• Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55:1090–1097.
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Johanson JF, Parkman HP, et al. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci. 2011;56:2639–2645.
   PubMed Web of Science ®Google Scholar
• Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35:587–599.
   PubMed Web of Science ®Google Scholar
• New drug for chronic constipation. FDA Consum. 2006;40:8.
   Google Scholar
• Lang L. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology. 2008;135:7.
   Web of Science ®Google Scholar
• Lin JE, Valentino M, Marszalowicz G, et al. Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics. Toxins. 2010;2:2028–2054.
   PubMed Web of Science ®Google Scholar
• Verkman AS, Galietta LJV. Chloride channels a drug targets. Nat Rev Drug Discovery. 2009;8:153–171.
   PubMed Web of Science ®Google Scholar
• Lin JE, Valentino M, Marszalowicz G, et al. Guanylate cyclase-C receptor activation: unexpected biology. Curr Opinion Pharmacol. 2012;12:632–640.
   PubMed Web of Science ®Google Scholar
• Hannig G, Tchernychev B, Kurtz CB, et al. Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain. Front Mol Neurosci. 2014;7:31.
   PubMed Web of Science ®Google Scholar
• Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3’,5’-monophosphate. Gastroenterology. 2013;145:1334–1346.
   PubMed Web of Science ®Google Scholar
• Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010;22:312–e84.
   PubMed Web of Science ®Google Scholar
• Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139:1877–1886.
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson OS, Gangarosa L, et al. Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2011;23:944–e400.
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527–536.
   PubMed Web of Science ®Google Scholar
• McWilliams V, Whiteside G, McKeage K. Linaclotide: first global approval. Drugs. 2012;72:2167–2175.
   PubMed Web of Science ®Google Scholar
• Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally within the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58:2580–2586.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Gores GJ. Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol. 2015;309:G209–G215.
   PubMed Web of Science ®Google Scholar
• Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139:1549–1558.
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013;22:277–284.
   PubMed Web of Science ®Google Scholar
• Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation–a double-blind study. Aliment Pharmacol Ther. 2011;34:41–50.
   PubMed Web of Science ®Google Scholar
• Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011;106:1803–1812.
   PubMed Web of Science ®Google Scholar
• Roarty TP, Weber F, Soykan I, et al. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther. 1997;11:1059–1066.
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Low P, Camilleri M, et al. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut. 2013;62:708–715.
   PubMed Web of Science ®Google Scholar
• Taghavi SA, Shabani S, Mehramiri A, et al. Colchicine is effective for short-term treatment of slow transit constipation: a double-blind placebo-controlled clinical trial. Int J Colorectal Dis. 2010;25:389–394.
   PubMed Web of Science ®Google Scholar
• Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet. 1991;338:1233–1236.
   PubMed Web of Science ®Google Scholar
• Jaffe IA, Hyman GA. Hematologic toxicity after the use of desacetylmethylcolchicine in the treatment of gouty arthritis. N Engl J Med. 1957;257:157–161.
   PubMed Web of Science ®Google Scholar
• Caldwell RW, Lowensohn HS, Chryssanthis MA, et al. Interactions of pyridostigmine with cardiopulmonary systems and their relationships to plasma cholinesterase activity. Fundam Appl Toxicol. 1989;12:432–441.
   PubMedGoogle Scholar
• Kenefick NJ, Nicholls RJ, Cohen RG, et al. Permanent sacral nerve stimulation for treatment of idiopathic constipation. Br J Surg. 2002;89:882–888.
   PubMed Web of Science ®Google Scholar
• Thomas GP, Dudding TC, Rahbour G, et al. Sacral nerve stimulation for constipation. Br J Surg. 2013;100:174–181.
   PubMed Web of Science ®Google Scholar
• Dinning PG, Hunt L, Patton V, et al. Treatment efficacy of sacral nerve stimulation in slow transit constipation: a two-phase, double-blind randomized controlled crossover study. Am J Gastroenterol. 2015;110:733–740.
   PubMed Web of Science ®Google Scholar
• Wexner SD, Daniel N, Jagelman DG. Colectomy for constipation: physiologic investigation is the key to success. Dis Colon Rectum. 1991;34:851–856.
   PubMed Web of Science ®Google Scholar
• Redmond JM, Smith GW, Barofsky I, et al. Physiological tests to predict long-term outcome of total abdominal colectomy for intractable constipation. Am J Gastroenterol. 1995;90:748–753.
   PubMed Web of Science ®Google Scholar
• Hassan I, Pemberton JH, Young-Fadok TM, et al. Ileorectal anastomosis for slow transit constipation: long-term functional and quality of life results. J Gastrointest Surg. 2006;10:1330–136.
   PubMed Web of Science ®Google Scholar
• Nyam DC, Pemberton JH, Ilstrup DM, et al. Long-term results of surgery for chronic constipation. Dis Colon Rectum. 1997;40:273–279.
   PubMed Web of Science ®Google Scholar
• Glia A, Akerlund JE, Lindberg G. Outcome of colectomy for slow-transit constipation in relation to presence of small-bowel dysmotility. Dis Colon Rectum. 2004;47:96–102.
   PubMed Web of Science ®Google Scholar
• Iturrino J, Camilleri M, Orrock JM. Mega-intestine after subtotal colectomy for constipation. Clin Gastroenterol Hepatol. 2011;9:A38.
   Google Scholar
• FitzHarris GP, Garcia-Aguilar J, Parker SC, et al. Quality of life after subtotal colectomy for slow-transit constipation: both quality and quantity count. Dis Colon Rectum. 2003;46:433–440.
   PubMed Web of Science ®Google Scholar
• Gladman MA, Scott SM, Lunniss PJ, et al. Systematic review of surgical options for idiopathic megarectum and megacolon. Ann Surg. 2005;241:562–574.
   PubMed Web of Science ®Google Scholar
• Ding W, Jiang J, Feng X, et al. Clinical and pelvic morphologic correlation after subtotal colectomy with colorectal anastomosis for combined slow-transit constipation and obstructive defecation. Dis Colon Rectum. 2015;58:91–96.
   PubMed Web of Science ®Google Scholar
• Li N, Jiang J, Feng X, et al. Long-term follow-up of the Jinling procedure for combined slow-transit constipation and obstructive defecation. Dis Colon Rectum. 2013;56:103–112.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Blandizzi C. Understanding and treating refractory constipation. World J Gastrointest Pharmacol Ther. 2014;5:77–85.
   PubMedGoogle Scholar
• Chiarioni G, Whitehead WE, Pezza V, et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130:657–664.
   PubMed Web of Science ®Google Scholar
• Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum. 2007;50:428–441.
   PubMed Web of Science ®Google Scholar
• Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol. 2007;5:331–338.
   PubMed Web of Science ®Google Scholar
• Rao SS, Valestin J, Brown CK, et al. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol. 2010;105:890–896.
   PubMed Web of Science ®Google Scholar
• Pourmomeny AA, Emami MH, Amooshahi M, et al. Comparing the efficacy of biofeedback and balloon-assisted training in the treatment of dyssynergic defecation. Can J Gastroenterol. 2011;25:89–92.
   PubMed Web of Science ®Google Scholar
• Hart SL, Lee JW, Berian J, et al. A randomized controlled trial of anorectal biofeedback for constipation. Int J Colorectal Dis. 2012;27:459–466.
   PubMed Web of Science ®Google Scholar
• Simón MA, Bueno AM. Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial. Appl Psychophysiol Biofeedback. 2009;34:273–277.
   PubMed Web of Science ®Google Scholar
• Farid M, El Monem HA, Omar W, et al. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Colorectal Dis. 2009;24:115–120.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang ZN, He L, et al. Botulinum toxin type-A injection to treat patients with intractable anismus unresponsive to simple biofeedback training. World J Gastroenterol. 2014;20:12602–12607.
   PubMed Web of Science ®Google Scholar
• Faried M, El Nakeeb A, Youssef M, et al. Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. J Gastrointest Surg. 2010;14:1235–1243.
   PubMed Web of Science ®Google Scholar
• Maria G, Cadeddu F, Brandara F, et al. Experience with type A botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol. 2006;101:2570–257.
   PubMed Web of Science ®Google Scholar
• Harris MA, Ferrara A, Gallagher J, et al. Stapled transanal rectal resection vs. transvaginal rectocele repair for treatment of obstructive defecation syndrome. Dis Colon Rectum. 2009;52:592–597.
   PubMed Web of Science ®Google Scholar
• Biviano I, Badiali D, Candeloro L, et al. Comparative outcome of stapled trans-anal rectal resection and macrogol in the treatment of defecation disorders. World J Gastroenterol. 2011;17:4199–4205.
   PubMed Web of Science ®Google Scholar
• Dodi G, Pietroletti R, Milito G, et al. Bleeding, incontinence, pain and constipation after STARR transanal double stapling rectotomy for obstructed defecation. Tech Coloproctol. 2003;7:148–15.
   PubMedGoogle Scholar
• Schwandner O, Fürst A. Assessing the safety, effectiveness, and quality of life after the STARR procedure for obstructed defecation: results of the German STARR registry. Langenbecks Arch Surg. 2010;395:505–513.
   PubMed Web of Science ®Google Scholar
• Madbouly KM, Abbas KS, Hussein AM. Disappointing long-term outcomes after stapled transanal rectal resection for obstructed defecation. World J Surg. 2010;34:2191–2196.
   PubMed Web of Science ®Google Scholar
• Quigley EM. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol. 2011;25:119–126.
   PubMed Web of Science ®Google Scholar
• Zhu L, Liu W, Alkhouri R, et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics. 2014;46:679–686.
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547–1561.
   PubMed Web of Science ®Google Scholar